Condition: Persistent, Recurrent, or Metastatic Cervical Cancer · Sponsor: Instituto Nacional de Cancer, Brazil
This is a phase II single-arm study of low-dose pembrolizumab (100mg, fixed-dose) plus chemotherapy in women aged 18 years or older with histologically confirmed persistent, recurrent, or metastatic cervical cancer who are ineligible for curative-intent treatment (surgery and/or radiation therapy) and who have not been previously treated with systemic chemotherapy, with the exception of chemotherapeutic agents used as radiosensitizers (cisplatin or carboplatin concurrent with radiation therapy).
This description comes directly from the study's public registry record.
Andreia C Melo, PhD · 552132072988 · andreia.melo@inca.gov.br
Cecilia F da Silva, PhD · 552132072988 · cecilia.silva@inca.gov.br
Always discuss trial participation with your own doctor first.
| Instituto Nacional de Cancer | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06670911